Abstract With the current epidemic of diagnosed pancreatic cystic neoplasms on the rise, a substantial amount of work has been done to unravel their biology, thus leading to implications on clinical decision making. Recent genetic profiling of resected human specimens has identified alterations in signaling pathways involving KRAS and GNAS signaling as early events in the pathogenesis of intraductal pancreatic mucinous neoplasms. Progressively, mutations in genes such as TP53, SMAD4, RNF43, and others are thought to characterize invasive and advanced lesions. The role of inflammation in fueling the growth and transformation of these cysts has also begun to be studied with greater interest. A number of promising clinical studies have attempted to integrate these genetic insights into classifying these cysts and treating patients. We have reviewed existing literature on similar lines besides commenting on some useful animal models that recapitulate molecular and phenotypic progression of these cysts.
Introduction
Due to increasing availability and use of cross-sectional imaging modalities, the diagnosis of pancreatic cystic neoplasms is on the rise. Over 2% of patients undergoing cross-sectional imaging will be found to have pancreatic cysts [1, 2] . Once discovered, primary care physicians, internists, and surgeons are faced with the complex challenge of management of these lesions. Research has shown that ''some'' of these cysts indeed have malignant potential. Thus, addressing these cysts surgically offers an opportunity to achieve, at least partially, the ever-elusive goal of preventing development of pancreatic cancer. However, not all cysts are premalignant, and the current modalities used to differentiate the premalignant cysts from those which are primarily benign (imaging, endoscopic ultrasound, and cyst fluid analysis) while helpful are not completely foolproof. This often leads to unnecessary surgeries accompanied with their associated complications. For example, up to 20% of pancreatic cysts resected due to concerns about their malignant potential, even at a high-volume center, were found to be benign on final pathology [3] . More importantly, the risk of development of cancer in premalignant cysts and the factors that drive development of cancer in these premalignant cysts are not known. This leads to surgical removal of many premalignant cysts, which may have never evolved into pancreatic adenocarcinoma and thus could have been safely observed. A better understanding of the pathogenesis of pancreatic cyst and their progression to malignancy will help make an accurate diagnosis and predict behavior. This review addresses our current knowledge of the pathogenesis of pancreatic cysts.
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Classification of Pancreatic Cysts
Pancreatic cysts can be classified into inflammatory and neoplastic subtypes. Inflammatory pancreatic cysts, the most common pancreatic cysts, are typically a local complication of severe pancreatic inflammation. Neoplastic cysts, the focus of the current review, are believed to represent 10-15% of cystic lesions [4] and have variable malignant potential. Overall, intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN), and serous cystadenoma (SCA) are the most common cystic neoplasms of the pancreas. IPMN and MCN are believed to potentially lead to pancreatic ductal adenocarcinoma, whereas SCA are largely benign.
Intraductal Papillary Mucinous Neoplasms
Intraductal papillary mucinous neoplasms or IPMNs are believed to arise from pancreatic ducts. IPMN is believed to be field defects and may manifest as diffuse or multi-focal involvement. The epithelial lining of the IPMNs demonstrates a spectrum of dysplasia ranging from low to high grade progressing to invasive cancer. Based on the site of origin, main pancreatic duct, branch ducts, or the mixture of both, these neoplasms have been classified into main duct IPMN (MD-IPMN), branch duct IPMN (BD-IPMN), or mixed type, where both main duct and branch duct are involved, respectively. This classification is not only of academic interest but actually helps predicts biology. The involvement of main duct, which is evident on the preoperative cross-sectional imaging, suggests more aggressive biology, and up to 60% of resected MD-IPMN will demonstrate carcinoma in situ and/or invasive cancer [4] . On the other hand, malignancy is reported in 12-30% of resected BD-IPMN [4] . If considered as a whole, malignancy risk may be even lower in BD-IPMN, as many of these are observed and only the most concerning are resected.
Detailed histopathological analysis has helped classify the IPMNs into gastric, intestinal, pancreatobiliary, and oncocytic papillary subtypes. Interestingly, this histopathological classification also co-relates with biology. Epithelial morphology in gastric subtype resembles gastric mucosa and is characterized by a low proliferative activity and consequently a lower risk of malignant transformation. This subtype is most commonly associated with BD-IPMN. Intestinal subtype, as the name suggests, recapitulates the epithelium of colonic villous adenomas. Many of the MD-IPMN bear this morphology, and invasive disease developing in this subtype gives rise to the colloid variety of PDAC. The most sinister pattern, however, is the pancreatobiliary subtype, which typically harbors high-grade dysplasia with invasive lesions developing to form tubular PDAC.
Mucinous Cystic Neoplasm (MCN)
Mucinous cystic neoplasms or MCNs are seen almost exclusively in females, are almost always solitary, and may be located in either the body or the tail of the pancreas. In contrast to IPMN, MCNs tend to be solitary and do not communicate with the pancreatic duct. The epithelial lining may exhibit varying degree of atypia, and based on this the cysts are classified into (1) mucinous cystadenoma; (2) mucinous cystic tumors; and (3) mucinous cystadenocarcinoma. One of the unique features of MCNs is the dense cellular ovarian-type stroma, which underlines the epithelium. This unique stroma may help distinguish MCNs from branch duct IPMN and is considered essential for the diagnosis of MCNs.
Serous Cystadenoma (SCA)
While there are occasional case reports of SCA metastasizing, these lesions are considered benign [4] . However, they can grow to enormous size and may produce local compressive effects, thus necessitating resection. Macroscopically, these lesions are described as microcystic with characteristic septations and thick fibrous wall giving them a honeycomb appearance. These cysts contain thin serous fluid in contrast to IPMN and MCN, which have thick mucinous fluid. The cysts are lined by thin glycogen-rich cuboidal epithelium. In total, 10-15% of SCAs are oligoor macrocystic, which can make them difficult to distinguish from MCNs or IPMNs [4] .
Genetic Makeup of IPMN
While ''environmental'' factors may initiate and/or drive the neoplastic transformation, genetic alterations are believed to be required for neoplasia. The -omics revolution has helped us decipher and quantitate these genetic changes, thus helping us understand the pathogenesis of various neoplasms. In this regard, cystic neoplasms of the pancreas are no exceptions. A variety of studies have evaluated the mutational profile of cystic neoplasms of the pancreas with the goal to get an insight into their pathogenesis. To understand the genetic mutation profile of IPMNs, Wu et al. [5] analyzed the sequence of 169 common cancer-related genes in cyst fluid from 19 IPMNs through massive parallel sequencing. The important mutations so discovered were further validated in additional 113 specimens that included cyst fluid and surgically resected specimens of cyst walls. In the initial limited evaluation, it was observed that only two genes were mutated in more than one IPMN, namely KRAS (14/19 specimens) and GNAS (6/19 specimens). All the KRAS mutations were at codon 12 (G12D, G12V or G12R) and those in GNAS were at codon 201 (R201H or R201C). While KRAS mutations have been described in IPMN before, this was the first report of GNAS mutation in IPMN. GNAS encodes for Gsa which forms a trimer with b and c subunits and is an integral part of signaling mediated by G protein-coupled receptors. GNAS mutation leads to disruption of the intrinsic hydrolytic activity of Gsa, which results in constitutive activation of its function. The frequency of KRAS codon 12 and GNAS codon 201 mutations was further validated in the validation set of genomic DNA obtained from cyst fluid or macro-and microdissected cyst walls. In this large set of IPMNs, 66% were found to have GNAS mutation and 81% were found to have KRAS mutations. Interestingly, 51% of IPMNs had both KRAS and GNAS mutations, whereas\5% did not have either. No KRAS or GNAS mutation was observed in serous cystic neoplasms studied in this study, suggesting that KRAS and/ or GNAS mutations may be required specifically for the formation of IPMNs. Furthermore, authors observed that there was no correlation between the grade of tumor and the mutation in GNAS and KRAS genes and that these mutations are also found in IPMNs with no evidence of malignancy. This suggests that these mutations are probably acquired early in the pathogenesis of IPMN, and additional mutations may be required for the disease progression. GNAS and KRAS were also found in 7 out of 8 pancreatic ductal adenocarcinoma developing in the setting of IPMN, suggesting that the clones evolving into cancer harbor mutations in these genes. This is in stark contrast to the previously published data on mutations in PDAC, developing in the absence of IPMN, where no GNAS mutation was observed [6] .
In another small study, Wu et al. [7] extended their previous work and used whole exome sequencing on eight IPMNs and matched normal tissues. Authors observed on an average 26 mutations per IPMN. Six genes were mutated in more than one IPMN patient in this small study. Besides reconfirming that KRAS and GNAS mutations are frequent in IPMNs, this study also demonstrated, for the first time, frequent mutation in RNF43. Mutations in RNF43, which is known to have intrinsic E3 ubiquitin ligase activity, were even more common than those in either KRAS or GNAS. RNF43 mutations were also observed in mucinous cystic neoplasm but not in SCN and SPN. These mutations were the result of both loss of heterozygosity (LOH) and base pair substitution.
Previous studies have suggested that besides activating mutations in KRAS, IPMN harbor inactivating mutations in many other genes including CDKN2A/p16 [8] , TP53, BRAF, PIK3CA [9] , and SMAD4 [8] . In a targeted nextgeneration sequencing (NGS)-based study by Amato et al.
[10], 52 specimens (48 IPMNs and 4 ITPNs) were studied after enriching for neoplastic cells. Immunohistochemistry (IHC) was used to validate the differential expression of CDKN2A/P16 and SMAD4 genes. Confirming previously published findings GNAS and KRAS mutations were the most prevalent alterations found in 75 and 46% of cases, respectively. Taken collectively 87% of cases harbored GNAS and/or KRAS mutations, and only 6 out of 52 samples, which were equally divided between samples with and without associated malignancy, did not have mutations in KRAS or GNAS. This suggests that, hitherto unknown, alternate early mutations may exist, which can initiate the development of IPMNs in a subset of patients. This study also demonstrated that mutations in RNF43 were third most common mutations and were always associated with mutations in KRAS or GNAS. Of note, this study did not comment on whether mutation in RNF43 varied with the grade of the lesion, which would have helped elucidate its role in the neoplastic progression of IPMNs. Mutations in the TP53 and BRAF were present in 10 and 6% of the specimens, respectively. It is worth noting that the specimens with TP53 and BRAF mutation harbored high-grade and/or malignant lesions, suggesting that these mutations are acquired later in the pathogenesis of IPMN and might be involved in its progression (Fig. 1a) . These data corroborate with previous studies, suggesting that the frequency of mutations in TP53 gene increases as the lesions progresses from adenoma to invasive disease [11, 12] .
Mutations in other genes including CTNNB1, IDH1, STK11, PTEN, ATM, CDH1, CDKN2A, FGFR3, NRAS, and SMAD4 were found at a much lower level of\4%. The involvement of CDKN2A/p16 and SMAD4 in pathogenesis of IPMN was further evaluated by IHC. Intriguingly, p16 loss on IHC increased with increasing grade of the lesions with 31% of intermediate grade and 53% of high-grade lesions demonstrated loss of p16, and none of the lowgrade lesions demonstrated p16 loss (Fig. 1a) . These data are similar to previous report where loss of p16 was found to increase as the disease progressed from noninvasive (10% samples with p16 loss) to invasive disease (100% loss of p16 in invasive disease) in IPMN [8] (Fig. 1a) . SMAD4 loss was observed in four IPMNs associated invasive cancers, but the neighboring noninvasive components had intact SMAD4. There is some controversy with respect to SMAD4 loss and IPMN. While an initial study in 79 patients suggested that SMAD4 is rarely lost even in the invasive cancer secondary to IPMN [13] , latter studies have suggested that SMAD4 does get deleted in IPMN with the development of cancer [8] .
Besides the mutations and pathways described above, a number of other pathways have been observed to be dysregulated in IPMN. Studies describing these pathways have generally taken a targeted rather than global approach (like whole exome sequencing). Phosphatidylinositol-3 kinases (PI3Ks) are an important group of lipid kinases, which regulate several growth-, invasion-, and metabolism-related signaling pathways. PIK3CA, which is a class IA PI3K, has been found to be mutated in several tumor types including gastric, colorectal, lung, and breast cancers [14] . Schonleben et al. [9] did a mutational profile on 36 IPMNs by direct genomic sequencing and observed that PIK3CA was mutated in 11% (4/36) specimens. Possibly due to small number of specimens, it could not be deciphered at what stage of the pathogenesis of IPMN these mutations are acquired.
Does GNAS Versus KRAS Mutation Analysis Predict Different Biology or Developmental Pathways?
IPMN is an important clinical entity due to the potential of it evolving into malignancy. Invasive cancer developing in IPMN, interestingly, has two distinct histopathologic subtypes with different prognoses. Patients with colloid carcinoma developing in patients with IPMN have markedly better prognosis when compared with patients who develop tubular carcinoma [15] . There is also a correlation between histological subtype of the IPMN and the histological subtype of malignancy. Colloid carcinoma typically arises from intestinal subtype of IPMN, whereas the tubular carcinoma arises from the pancreatobiliary subtype [16] . Interestingly, studies suggest that mutation profile may drive the specific histopathology of the IPMN as well as the invasive cancer developing in them. Wu et al. [5, 7] observed that while GNAS and KRAS mutations are present in all three histological subtypes of IPMN (intestinal, pancreatobiliary, and gastric), GNAS mutations predominate in intestinal subtypes and KRAS mutations are present in 100% of pancreatobiliary, 83% of gastric but only 39% of intestinal subtype of IPMN. In a study by Tan et al. [17] , where the mutation profile of IPMN and that of invasive component developing in them was determined by targeted massive parallel sequencing, GNAS mutations were more prevalent in colloid carcinoma as compared to tubular subtype (89 vs. 52%). GNAS mutations were also found to 
Inflammatory Pathways and IPMN
Recent evidence suggests that progression of pancreatic cyst dysplasia and inflammation may be intricately related. Maker et al. [19] performed inflammatory cytokine analysis on cyst fluid recovered from resected IPMNs from 40 patients. The authors observed that IFN-c and IL-4 were present at very low levels, and IL-2, IL-10, IL-12, IL-13, and TNF-a were present at higher levels. However, none of these cytokines correlated with degree of dysplasia in the specimens. Interestingly, univariate analysis suggested that IL-1b and IL-5 were present at higher levels in high-risk cysts. IL-1b levels remained significant predictor of highrisk versus low-risk cysts even after adjusting for IPMN subtype (main duct vs. branch duct) and cyst size. At a cutoff point of 1.26 qg/ml, IL-1b levels were 79% sensitive and 95% specific in distinguishing high-risk versus lowrisk cyst. Authors validated these results in a blinded fashion on an additional set of 15 patients and demonstrated that IL-1b levels of 1.26 qg/ml had a positive predictive value of 71% and negative predictive value of 75% to distinguish high-risk from low-risk lesions. In this study IL-1b was barely detectable in non-mucinous serous cystadenomas, which have a very low if any malignant potential. It must be noted that IL-1b is a major cytokine that is produced by activated inflammatory cells (primarily monocytes) and has been found to be related to carcinogenesis and chronic inflammation in a number of cancers. Sadot et al. [20] evaluated the association of neutrophil infiltration and malignant progression in IPMN. IPMN lesions were classified as tumor-associated neutrophil (TAN) negative (with 10 or fewer neutrophils per 100 tumor cells), low TAN (with 11-15 TANs per 100 tumor cells), and high TAN (with more than 15 TANs per 100 tumor cells). All the patients with invasive disease were TAN positive, and 90% had high TAN. These data, while not causal, again support a strong association of inflammation and disease progression in IPMNs. In another study [21] , endoscopic ultrasound (EUS)-guided fine-needle aspirate (FNA) specimens from pancreatic cyst fluids were used to characterize and compare inflammatory cytokines and proteins in inflammatory cysts and BD-IPMNs. In a small set of five patients each with either inflammatory cysts or IPMNs, the authors found seven cytokines to be elevated only in BD-IPMN. These were 6Ckine (chemokine with six cysteines), CTACK (cutaneous T cellattracting chemokine), ENA-78 (epithelial-derived neutrophil-activating protein 78), IL-20, IL-28A, MIP-3a (macrophage inflammatory protein 3-alpha), and MIP-3b. Conversely, 11 inflammatory cytokines were elevated exclusively in inflammatory cysts including M-CSF, I-309 (T lymphocyte-secreted protein), IL-17, IL-5, IL-9, TGFb1 (transforming growth factor beta-1), TGF-b2, TGF-b3, TNF-b, TPO (thyroid peroxidase), and TSLP (thymic stromal lymphopoietin). Of note though, from a total of 89 cytokines assayed, a majority of these cytokines were found to be elevated in both types of lesions suggesting a common inflammatory milieu that may be shared by both inflammatory cysts and pre-neoplastic pancreatic IPMNs. This limited analysis also suggested that granulocyte macrophage colony-stimulating factor (GM-CSF) and hepatocyte growth factor (HGF) in EUS-FNA-collected pancreatic cyst fluid could distinguish BD-IPMN from inflammatory cysts.
Genetic Profiling of Mucinous Cystic Neoplasms
As mentioned above, besides having cysts with varying degree of atypia in epithelial lining, MCNs have a unique ovarian like stroma. Thus, understanding of the pathogenesis of MCNs requires an understanding of the development of unique stroma. MCNs harbor many of the same mutations as seen in IPMNs and pancreatic ductal adenocarcinoma with some unique differences. Wu et al. [7] demonstrated that in their whole exome analysis of eight patients with MCN on an average, 16 mutations were discovered in each sample, which were more than SCAs but less than that in IPMNs. Similar to that in IPMNs, KRAS mutations were the most common and were observed in 75% of the samples. However, unlike that in IPMNs, GNAS mutations were not observed. Both TP53 and RNF43 mutations were also observed. Similar to that in IPMNs, KRAS mutations are believed to be early event in the pathogenesis of MCNs as even the lesions with lowgrade dysplasia harbor KRAS mutations [22] . On the other hand, p53 mutations are only observed in malignant lesions, suggesting that they may have a role in evolution of the invasive component [22, 23] . SMAD4 or DPC4 is intact in the noninvasive epithelium of MCN but is lost in the invasive component [24] . Similarly, PIK3CA mutations occur in higher-grade lesions in MCNs [25] .
While mutational profile of the ovarian stroma has not been performed, gene expression analysis of the ovarian stroma of MCN demonstrates overexpression of multiple genes. Stroma of MCNs overexpress several genes involved in estrogen metabolism including STAR and ESR1 [26] . Secreted Frizzled-related protein is also overexpressed in ovarian-type stroma of MCNs [26] . Wnt signaling has been found to be activated in the stroma of MCNs [27] . In mouse models, overexpression of Wnt1 in pancreatic acinar cells and acinar cells progenitors leads to development of cystic lesions, which resemble MCNs, and have Wnt receptor-and progesterone receptor-positive ovarian stroma [27] .
Genetic Profiling of Serous Cystadenoma
In contrast to IPMN and MCNs, SCAs are considered benign without any malignant potential. Wu et al. [7] studied the exome sequence of DNA from the neoplastic epithelium of eight resected SCAs. They observed that SCAs have 10 ± 4.6 mutations per tumor. Only two mutations were present in more than one SCA. Four out of eight SCAs had mutation in von Hippel-Lindau gene (VHL). Three of these four demonstrated LOH of the VHL chromosomal region. Allelic deletion and mutations in the VHL gene have been described previously in SCAs [28] . This is interesting as SCAs are commonly associated with patients with VHL syndrome and mutations in VHL have been described in the pancreatic cysts obtained from patients with VHL syndrome [29] . The association of VHL mutations with SCNs has interesting implications. For one, SCNs are found in as many as 15% hereditary VHL syndrome along with other tumors like renal clear cell carcinoma. In fact, Pdx1-Cre; Vhlh lox/lox mice with pancreas-specific VHL deletion infrequently develop cystic adenomas in pancreas [30] . VHL mutations lead to upregulation of vascular endothelial growth factor (VEGF)-1, hypoxia-inducible factor 1 alpha (HIF1-a), carbonic anhydrase IX (CAIX), and glucose transporter (GLUT)-1. This may be responsible for the clear cell nature of and the prolific angiogenesis in the tumors in VHL syndrome. Intriguingly, the four samples from SCA patients which did not harbor a clear VHL mutation had lost one allele of chromosome 3p within or adjacent to VHL gene. It is possible that in these patients VHL gene was inactivated by genetic alterations such as deletions or translocations, which will not be detectable by methods employed in the study. In this study, the authors were also able to identify VHL mutations in the fluid from 50% of patients with SCAs. TBC1D3 was the other gene mutated in two of the eight samples in this series. TBC1D3 is a member of the TBC1 domain family and encodes for the GTPase-stimulating proteins. While application of TBC1D3 is described in prostate cancer, the significance of this gene in the pathogenesis of SCAs is unknown.
It must be noted that the genetic alterations seen in pancreatic ductal adenocarcinoma (KRAS, TP53, SMAD4), IPMNs (KRAS, GNAS, RNF43), and MCNs (KRAS) are not seen in SCAs. This not only sheds light on unique pathogenesis of these cysts but also has clinical significance as this unique profile can be used to diagnose these cysts in patients where the radiologic findings are equivocal and thus prevent unnecessary resection of asymptomatic SCAs. Springer et al. [31] did a mutational analysis of cyst fluid and found that VHL mutations were detectable in 42% of SCAs, with 64% them demonstrating LOH at VHL locus and 8% of showing aneuploidy at 3p locus. Other SCAs did not have any significant mutation. The authors' analytic algorithm found out that an absence of KRAS, GNAS, RNF43 mutations, or lack of aneuploidy in 5p or 8p loci helped predict the presence of SCA with high sensitivity and specificity.
Lessons from Mouse Model
Mouse models help understand the critical role of the genetic mutations in the pathogenesis of neoplastic disease. Further, development of such models also provides a platform for basic and translational research into the pathogenesis and therapeutics of the disease. While a lot of progress has been made in the generation of genetic models of pancreatic carcinogenesis, there has been dearth of valid models of cystic neoplasms of the pancreas. However, with the new found understanding of the genetic makeup of pancreatic cystic neoplasms, new models are being increasingly described. As discussed above, there has been increasing understanding of the role of GNAS in the development of IPMNs. To investigate the role of GNAS, Taki et al. [32] generated conditional transgenic mouse lines where, in the presence of Cre recombinase, wild-type GNAS or GNAS with R201H mutation was expressed. These mice when crossed with Ptfa Cre/? expressed WT or mutated GNAS in pancreatic progenitor cells. Interestingly, in this model induction of mutated GNAS led to ectasia of main pancreatic duct, fibrosis, and acinar atrophy which could represent an early phenotype of IPMN. However, these mice did not develop macroscopic tumors when followed for up to 2 months. This again supports that while GNAS mutation may be necessary, it may not be sufficient to develop full-blown IPMN. The authors also evaluated the effect of introduction of KRAS G12D in addition to GNAS in a pancreas-specific manner by crossing the above-mentioned mice with LSL-Kras G12D mice. Interestingly, Tg(CAG-LSL-GNAS R201H ); LSL-Kras G12D ; Ptf1a Cre/? mice developed ascites and pancreatic tumor starting 5 weeks of age, and these mice had significantly shortened life span compared to the parent mouse lines. On histopathology, the tumors had typical IPMN-like features: dilated ducts, lowto high-grade papillae consisting of epithelial cell and extensive inflammation. Notably, like gastric or pancreatobiliary IPMNs, papillae showed strong positive staining for mucus core protein (MUC)1 and MUC5AC and phosphorylated substrates of protein kinase A. While *50% of patients may have both KRAS and GNAS mutations, this model may not recapitulate biology of *50% of patients who do not have both KRAS and GNAS mutations.
Activating KRAS mutations alone faithfully recapitulate PanIN lesions but do not lead to the development of pancreatic cysts by themselves, and additional mutations are needed. Siveke et al., overexpressed TGFa (driven by elastase) in addition to KRAS G12D in the pancreas (miceexpressing Cre under control of p48) and observed that this led to accelerated PanINs formation as well as development of cystic neoplasms reminiscent of human IPMNs. These cystic lesions contained mucin and were positive for MUC1 and 5AC, thus mimicking the pancreatobiliary subtype of human IPMNs. Interestingly, a significant number of these animals went on to develop invasive disease from both PanINs and IPMN lesions, as seen in human disease. Similar to that observed in human IPMNs [33] , activation of several EGFR-dependent oncogenic pathways was observed in this mice model. However, activating mutations of TGFa have not yet been shown to be present in IPMNs in humans so the relevance of this model to human disease is unclear.
To study the role of TGF-b in pancreatic carcinogenesis, Vincent et al. knocked out transcription intermediary factor 1-gamma gene (Tif1c) in the pancreas of mice with constitutively active KRAS. This model is characterized by abundant PanINs early on which are soon replaced by numerous cystic lesions. While there was a latency of *7 weeks in development of these cystic lesions, the penetrance was 100%. Many of the cells lining these cysts stained positively for cytokeratin (CK)19 as well as alcian blue suggesting a mucus secreting ductal origin of these lesions. In the absence of an ovariantype stroma, the lesions are more homologous to the human IPMN. Interestingly, IPMN-like lesions in this mouse model also have an endocrine component. Uncharacteristically, none of the IPMNs progressed into PDAC in the mice at the end of 13 weeks, and while Tif1c expression levels are reduced in pancreatic cancer, mutations in this gene have not been observed in IPMNs. The significance of these mutations is yet to be fully explored in terms of human disease. Cre/? (KD) mouse. While the KRAS mutation induced low-grade PanINs, the body and tail of the pancreata of these mice had grossly palpable cysts that could be 2-3 mm in size and are full of serous and/or hemorrhagic fluid. There were fewer metastases seen in this model compared to the KPC mouse model, an extensively described genetic model of PDAC. The cyst walls were characterized by columnar, CK19, and alcian-blue-positive mucin-secreting epithelial cells without any papillae as seen in IPMNs. Additionally, the stroma of these cysts was characteristic ovarian-type and consisted of desmin and SMA-expressing spindle-shaped cells with wavy nuclei, both of which are hallmarks of MCNs. KRAS LSL-G12D/? ; Dpc4 flox/flox p48 Cre/? (KDD) mice with both Dpc4 alleles deleted have an even more aggressive tumorigenic phenotype (average survival of 8 months vs. 15 months in KD mouse). KDD mice develop extensive PDAC lesions through a probable MCN to PDAC route. These lesions had upregulated expression of Egfr, Her2/neu, Shh, and Hes1. Compared to cell lines derived from KPC mice tumors, fewer cell lines could be successfully derived from KD mice and had a significantly higher doubling time. Also, these cell lines showed evidence of greater genomic stability than cell lines derived from KPC mice. The transcription of p16
Ink4a was frequently lost in many derived cell lines and was associated with a wild-type Trp53. A major mechanism underlying such gene silencing was found to be epigenetic and in some cases, genomic deletion, where p16
Ink4a locus was frequently methylated and silenced. Phenotypically, KD or KDD cell lines showed differential effects to TGFb stimulation compared to KPC cells. In KD cells, TGFb did not increase the motility of cells as much as in KPC. Importantly, this model helps in elucidating a pathway from MCNs to PDAC that is different from the classical one and depends on timing of the DPC4 mutation. It appears that mutation in TRP53 and/or p16, after initiating KRAS G12D mutation, leads the tumor cells down a canonical PDAC fate, and an additional DPC4 mutation only makes the cancer more aggressive. In contrast, a silencing mutation in DPC4 early on, i.e., after KRAS
G12D
, leads the cell to a MCN phenotype with decreased proliferation and migration.
Clinical Implications and Future Directions
The goal of gaining a detailed understanding of the pathogenesis of neoplastic cysts and the pathways leading to cancer development is to (1) employ -omics approach to help in correctly diagnosing the type of cyst; (2) help in detecting whether cancer has already developed in these lesions, thus providing a clear indication for surgical approach; (3) predict the biology of lesions with respect to progression to invasive lesions; and (4) attain the elusive goals of developing pharmacotherapy which may prevent development of invasive lesions. Typically, the correct diagnosis with respect to the nature of the cyst is made with help of cross-sectional imaging, endoscopic ultrasound with cyst fluid analysis including carcinoembryonic antigen (CEA) and cytology [4] . To improve the diagnostic and predictive ability, investigators have turned to molecular analysis. Initial studies involving the molecular markers in the cyst fluids have focused on predicting the risk of malignancy in mucinous cysts with high CEA. To this end, the studies suggest that increased DNA content, presence of KRAS mutation, or two or more loci of LOH were associated with mucinous neoplasms and that KRAS mutation followed by allelic loss is a strongly predictive of a malignant cyst [34] . Based on these findings, a molecular test PathFinder TG Ò is being increasingly promoted, though with only marginal, if any benefit in surgical decision making. In a recent study, Springer et al. [31] performed cyst fluid analysis to identify mutations in BRAF, CDKN2A, CTNNB1, GNAS, KRAS, NRAS, PIK3CA, RNF43, SMAD4, TP53, and VHL, to identify LOH at CDKN2A, RNF43, SMAD4, TP53, and VHL, and to identify aneuploidy, and this information was used to select markers that could classify cyst type and grade. This study was based on the previous elucidation of genetic makeup of SCA, MCN, IPMN, and solid pseudopapillary neoplasm [5, 7] , thus highlighting the importance of defining the pathogenesis and progression pathways. The authors then used multivariate organization of combinatorial alterations to identify composite molecular markers to help correctly diagnose the cyst subtype as well as the cysts which need surgical resection. This study suggested that combination of molecular markers including presence of VHL mutation or chr3 LOH and/or absence of KRAS, GNAS, RNF43 mutations, chr5p and chr8p aneuploidy detected SCA with 100% sensitivity and 91% specificity. Combination of absence of CTNNB1, GNAS mutations, chr3 LOH and chr1q and chr22q aneuploidy suggested a diagnosis of MCN with 100% sensitivity and 75% specificity. The presence of any of the following: GNAS, RNF43, chr9 LOH, chr1q, and chr8p aneuploidy detects IPMN with 76% sensitivity and 97% specificity. Addition of clinical parameters increased sensitivity while decreasing specificity. More importantly, the authors used a combination of molecular markers to predict need for surgical resection, i.e., identification of MCN, IPMN with high-grade dysplasia or invasive component or solid pseudopapillary neoplasm. A combination of mutations in SMAD4, TP53, chr17 LOH (region containing RNF43) or aneuploidy in chr5p, 8p, 13q or 18q, chr17 LOH was used as a marker of IPMN with high-grade dysplasia or invasive component. These mutations along with the molecular markers for MCN and solid pseudopapillary neoplasm were used to evaluate the ability of molecular diagnostics to correctly identify the lesions needing surgical resection. The study demonstrated that the combination of these molecular markers correctly identified patients requiring surgical intervention with 75% sensitivity and 92% specificity. This study suggests that sometime in the near future, molecular diagnostics may help in clinical decision making in pancreatic cyst evaluation. However, for now these molecular features only identify cysts which need surgical intervention at the time of evaluation. They do not predict the progression and evolution of these cysts. Future studies will be needed to identify markers of progression of dysplasia or even development of invasive component.
Conclusion
The current epidemic of pancreatic cystic neoplasms is a difficult clinical by-product of our expanding diagnostic capabilities. They range from asymptomatic benign incidental lesions to rapidly growing tumors with significant malignant potential. As such, diagnosing and managing pancreatic cystic neoplasms is a challenging clinical exercise in the absence of reliable markers of malignant progression and as yet an incomplete understanding of its pathophysiology. Recent efforts from clinical studies have identified key molecular driver mutations like KRAS and GNAS as early events. These findings along with mouse models that recapitulate morphological and natural history of progression from cystic lesions to malignancy is helping paint a clearer picture of this disease. Future studies will integrate our understanding of molecular changes in benign versus premalignant cysts to prognosticate and manage patients effectively.
